Investors Overview

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types.

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Upcoming Events

October 6, 2022 at 10:40 am EDT
BMO Biopharma Spotlight Series: Gene Editing & Therapeutics

November 29 - December 1, 2022
Evercore ISI HealthCONx Conference

more events